Tags

Type your tag names separated by a space and hit enter

COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 03 28; 395(10229):1033-1034.Lct

Authors+Show Affiliations

Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.Hospital for Tropical Diseases, University College London Hospital, London NW1 2PG, UK.Department of Clinical Virology, University College London Hospital, London NW1 2PG, UK.Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.Department of Rheumatology, University College London Hospital, London NW1 2PG, UK. Electronic address: jessica.manson@nhs.net.No affiliation info available

Pub Type(s)

Letter

Language

eng

PubMed ID

32192578

Citation

Mehta, Puja, et al. "COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression." Lancet (London, England), vol. 395, no. 10229, 2020, pp. 1033-1034.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Mehta P, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet. 2020 03 28;395(10229):1033-1034. PubMed PMID: 32192578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19: consider cytokine storm syndromes and immunosuppression. AU - Mehta,Puja, AU - McAuley,Daniel F, AU - Brown,Michael, AU - Sanchez,Emilie, AU - Tattersall,Rachel S, AU - Manson,Jessica J, AU - ,, Y1 - 2020/03/16/ PY - 2020/03/08/received PY - 2020/03/11/accepted PY - 2020/3/21/pubmed PY - 2020/4/4/medline PY - 2020/3/21/entrez SP - 1033 EP - 1034 JF - Lancet (London, England) JO - Lancet VL - 395 IS - 10229 SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/32192578/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)30628-0 DB - PRIME DP - Unbound Medicine ER -